Prediction of Progression of Age-Related Macular Degeneration
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Nov 17, 2020
Trial Information
Current as of May 12, 2025
Unknown status
Keywords
ClinConnect Summary
More than 90% of patients with advanced AMD have severe vision loss. Predicting AMD progression from an early or intermediate stage is crucial, since prompt intervention after a choroidal neovascularization (CNV) event and geographic atrophy (GA) monitoring can greatly improve visual outcomes. Patients at higher risk of progression should have more frequent follow-up visits, since progression often occurs before any visual changes are noticed by the patient. Previous work has determined the risk factors for AMD progression based on drusen features in fundus photos, Optical Coherence Tomogra...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Non-neovascular AMD at baseline in at least one eye with no signs of GA,
- • \> 45 years of age,
- • willingness to participate through a signed consent form.
- Exclusion Criteria:
- • Pregnant women and vulnerable populations
- • Participation in an investigational trial that involves treatment with any drug (with the exception of vitamins or minerals) within 3 months prior to Day 1.
- • Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Joelle A Hallak, PhD
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials